Abstract
The case of a patient who developed neuroleptic malignant syndrome (NMS) on three separate occasions is presented. Her third bout of this syndrome possibly was caused by molindone hydrochloride. This medication has been reported only once previously to cause NMS. The pharmacology of molindone is reviewed and a complicating factor in this case—the recent onset of hypothyroidism—is discussed together with its implication in the development of the clinical manifestations of this syndrome.
Get full access to this article
View all access options for this article.
References
1.
Guze
BH
Baxter
LR
. Neuroleptic malignant syndrome . N Engl J Med
1985 ; 313 : 163 –6 .
2.
Rosebush
PI
Steward
TD
Gelenberg
AJ
. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in fifteen patients . J Clin Psychiatry
1989 ; 50 : 295 –8 .
3.
Bernstien
R
. Malignant neuroleptic syndrome—an atypical case . Psychosomatics
1979 ; 20 : 840 –6 .
4.
Pandurangi
AK
Narasimhachari
N
Blackard
WA
Landa
BS
. Relation of serum molindone levels to serum prolactin levels and antipsychotic response . J Clin Psychiatry
1989 ; 50 : 379 –81 .
5.
Claghorn
JG
. Review of clinical and laboratory experiences with molindone hydrochloride . J Clin Psychiatry
1985 ; 46 : 30 –3 .
6.
Lavie
CJ
Olmsted
TR
Ventura
HO
Lepler
BJ
. Neuroleptic malignant syndrome—an underdiagnosed reaction to neuroleptic agents?
Postgrad Med
1986 ; 80 : 171 –8 .
7.
Meller
E
. Chronic molindone treatment: Relative inability to elicit dopamine receptor supersensitivity in rats . Psychopharmacology
1982 ; 76 : 222 –7 .
8.
Peper
M
. Clinical experience with molindone hydrochloride in geriatric patients . J Clin Psychiatry
1985 ; 46 : 26 –9 .
